Prof Paul E Squires
LightNews LightNews
banner
paulsquires.bsky.social
Prof Paul E Squires
@paulsquires.bsky.social
970 followers 260 following 17 posts
Prof of Biomedical Science with interests in diabetes, cardiorenal & kidney disease, connexins & cell-cell contact, coupling & communication. Views are my own. 👨‍🔬🔬🇬🇧 #cardiosky #nephsky #diabetes #cardiorenal
Posts Replies Media Videos
Reposted by Prof Paul E Squires
droch.bsky.social
Our department @ucph.bsky.social is looking for a new faculty member! This is a nice environment for an ambitious PI with a research focus on cardiovascular system, metabolism and/or drug discovery! Happy to answer questions if you are interested!
164414 Tenure Track Assistant Professor or Associate Professor of Biomedical Sciences
jobportal.ku.dk
July 4, 2025 at 10:19 AM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Wedding Vibes 👰🤵‍♂💒💍 with @paulsquires.bsky.social ..it was a hot one ☀️☀️☀️ #ArdingtonHouse #Oxfordshire #womeninSTEM #annualleave #summertime #UK #Cotswolds #wedding
July 11, 2025 at 9:31 PM
Reposted by Prof Paul E Squires
braithwaiteat.bsky.social
Stimulating immune cells in vitro is a common experimental lab model. We profiled 150K blood immune cells treated with 11 different stimuli to compare the effects. The data are freely available for researchers. See the preprint for our findings and to access the data 🧪 doi.org/10.1101/2025...
July 3, 2025 at 3:39 PM
Reposted by Prof Paul E Squires
struangrant.bsky.social
Delighted to have contributed to this editorial
diabetesjournals.org/diabetes/art...
Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic Data
In the last two decades, significant progress has been made toward understanding the genetic basis of type 2 diabetes. An important supporter of this resea
diabetesjournals.org
April 24, 2025 at 5:32 PM
paulsquires.bsky.social
Fantastic article to celebrate the contribution of our very own @chillslincoln79.bsky.social to some amazing work on #worldkidneyday, see:
news.lincoln.ac.uk/2025/03/13/l...
Lincoln Professor Helping Shape the Future of Diabetic Kidney Disease Research | News and PressPrevious posts arrow navigation.Next posts arrow navigation.
Browse through a range of inspiring news stories from the University of Lincoln, featuring leading research, campus events, and student and alumni success stories.
news.lincoln.ac.uk
March 13, 2025 at 1:40 PM
Reposted by Prof Paul E Squires
nictitate.bsky.social
I have funding through at least 2031 for postdoctoral researchers with expertise in islet biology or cell-based therapies for, or modelling of, diabetes. Bring your expertise to a country that values it. 🇨🇦

Contact info on my website.
February 15, 2025 at 4:40 PM
Reposted by Prof Paul E Squires
bruceverchere.bsky.social
Fantastic opportunity for fellowship in an excellent T1D research training environment working in regenerative medicine and stem cells in the Breakthrough T1D Centre of Excellence at UBC. If you missed the NOI deadline, no worries, you can still apply! Reach out if you have any questions.
stemcellnetwork.ca Stem Cell Network @stemcellnetwork.ca · Feb 10
Are you applying for the J. Andrew McKee Fellowship in Type 1 Diabetes? 
 
Supported by SCN and Breakthrough T1D (formerly JDRF), this is your chance to join UBC’s Breakthrough T1D Centre of Excellence.

Submit your application by February 27, 2025. ➡️ stemcellnetwork.ca/training/exc...
J. Andrew McKee Fellowship in Type 1 Diabetes
February 10, 2025 at 8:55 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Effect of #sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial 👩‍🔬🥼🧪👨‍🔬 #cardiosky #SGLT2i #SGLT1/2 #cardiovascular #womeninstem #NephSky 👇👇👇

www.thelancet.com/journals/lan...
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The ischae...
www.thelancet.com
February 16, 2025 at 10:45 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
A sunday night worth celebrating with @paulsquires.bsky.social after a busy, busy week 🥂🍾. Hopeful that good news will follow 👩‍🔬👨‍🔬🧪 #justbecause #cardiosky #NephSky #womeninSTEM #academic #weekendvibes #champagne ##KidneyResearch #CardioRenal #Cardiovascular
February 16, 2025 at 6:58 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Birthday boy cotswolds celebrations 🥳🥳 @DoubleRedDuke with @paulsquires.bsky.social 🥰🥰 #birthday #cotswolds #England #annualleave #womeninSTEM
February 2, 2025 at 5:36 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
📣 Novo Nordisk announces that the FDA has granted approval to its blockbuster drug Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes. 👩‍🔬🥼🧪👨‍🔬

#Semaglutide #diabetes #type2diabetes #nephropathy #GLP-1 👇👇

docwirenews.com/post/fda-app...
FDA Approves Ozempic for Kidney Disease | Docwire News
Based on FLOW trial results, the FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
docwirenews.com
January 28, 2025 at 9:46 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
📣 Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-clinical trial @naturemedicine.bsky.social 👩‍🔬🥼🧪👨‍🔬 #Semaglutide #KidneyDisease #Obesity #kidney #NephroSky #CardioSky #NephSky 👇👇👇
pubmed.ncbi.nlm.nih.gov/39455729/
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial - PubMed
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind ...
pubmed.ncbi.nlm.nih.gov
January 29, 2025 at 6:16 PM
paulsquires.bsky.social
BBC News - Meon Vale mother of three who needs kidney makes donor appeal - BBC News
www.bbc.co.uk/news/article...
Meon Vale mother of three who needs kidney makes donor appeal
Amber Simmonds, 29, has lived with hereditary polycystic kidney disease (PKD) since she was 13.
www.bbc.co.uk
January 29, 2025 at 9:41 PM
Reposted by Prof Paul E Squires
kidney.org
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
www.cnbc.com
January 28, 2025 at 8:21 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Congratulations @cardiacshah.bsky.social & co-author @jo-ward08.bsky.social from team #CardioRenal on publication of this all important review - incorporating clinical guidelines with latest evidence & experience in the management of T2DM in patients with ASCVD 🥳🥳🥳🥳. #diabetes #CardioSky #NephSky
cardiacshah.bsky.social Usman @cardiacshah.bsky.social · Jan 22
www.frontiersin.org/journals/end...

Pleased to see this review article getting published where we incorporate clinical guidelines with latest evidence and experience in the management of T2DM in patients with ASCVD. Very grateful to all the coauthors for the help and input.
Frontiers | Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
www.frontiersin.org
January 25, 2025 at 7:03 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Beautiful
#Salcombe, it never disappoints. The perfect place to switch off and unwind with @paulsquires.bsky.social 🥰🥰 #Lifeofanacademic #AcademicSky ##CardioSky #WomeninSTEM #England #Devon #SalcombeHarbour #Coastal #Coastline #NephroSky
January 23, 2025 at 5:00 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
📣 Congratulations to my PhD student @cardiacshah.bsky.social on his review 'Diagnosis & management of type 2 diabetes mellitus in patients with ischaemic heart disease & acute coronary syndromes - a review of evidence & recommendations' 👇👇 #CardioSky #diabetes

www.frontiersin.org/journals/end...
Frontiers | Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
www.frontiersin.org
January 22, 2025 at 9:44 AM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Checking out of all things work for the next 9 days with @paulsquires.bsky.social. Heading to Salcombe for sea air, coastal walks and yummy food and wine 🫒🍲🥖🥂🍷. Stay tuned for glorious pictures of the English Coast 🌊🌊 #FancyPants are on 😉 #WomeninSTEM #Weekend #Salcombe #England #Coastal
January 18, 2025 at 6:05 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Bracing but beautiful day in Salcombe with @paulsquires.bsky.social ❤️ #Salcombe #Devon #AnnualLeave #womeninSTEM #CardioSky #NephroSky
January 20, 2025 at 2:53 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Our special issue for DiabeticMedicine entitled 'From Bench to Bedside: An integrated and multi-disciplinary approach to tackling diabetic kidney disease' is available online now. 👇👇 #KidneyDisease #Diabetes #NephSky #KidneyResearch #Diabetes #CardioSky

onlinelibrary.wiley.com/toc/14645491...
<em>Diabetic Medicine</em> | Diabetes UK Journal | Wiley Online Library
Click on the title to browse this issue
onlinelibrary.wiley.com
January 16, 2025 at 4:29 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
A glorious walk today, albeit a slightly freezing day in Kenilworth. ❄️❄️❄️ #academicsky #cardiosky #nephsky #Warwickshire #saturday #countrylife #womeninSTEM
January 11, 2025 at 8:32 PM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
3 days back at work. Let's just say this wine is well deserved 🤣🤣. Thank heavens I have @paulsquires.bsky.social by my side to keep me sane 😬 #WomeninStem #cardiosky #Nephsky #academiclife #drama #womeninnephro
January 8, 2025 at 6:25 PM
Reposted by Prof Paul E Squires
leerobertslab.bsky.social
Metabolite-mediated inter-tissue signalling. Led by Jane Luk & Mark Kearney @unileedsnews.bsky.social in @naturecomms.bsky.social we identify malonic acid as an IGF1R-regulated endothelial-to-adipocyte metabokine mediating adipose metabolism. Great start to 2025.
www.nature.com/articles/s41...
Paracrine role of endothelial IGF-1 receptor in depot-specific adipose tissue adaptation in male mice - Nature Communications
Here the authors show that lowering IGF-1R levels in endothelial cells improves insulin sensitivity, boosts energy use, and supports beneficial changes in adipose tissue, offering insights into potent...
www.nature.com
January 3, 2025 at 9:16 AM
Reposted by Prof Paul E Squires
chillslincoln79.bsky.social
Interested in #GLP-1 , #Semaglutide #cardiovascular and #kidneydisease ? 👩‍🔬🥼🧪🧪Just out @thelancet.bsky.social 👇👇.

Thanks for sharing @paulsquires.bsky.social 👍

#CardioSky #NephSky #diabetes #kidneys #womeninSTEM
January 2, 2025 at 8:25 PM
paulsquires.bsky.social
Great read to start 2025 #GLP1 #semaglutide #diabetes #diabetesuk #cardiorenal #GLP1RA
www.thelancet.com/journals/lan...
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.
www.thelancet.com
January 2, 2025 at 5:21 PM